516
Views
0
CrossRef citations to date
0
Altmetric
Biochemistry, Cell and Molecular Biology

Alpha-cyano-4-hydroxycinnamic acid alleviates renal fibrosis and inflammation in chronic kidney disease

, , &
Article: 2236310 | Received 23 Sep 2021, Accepted 08 Jun 2023, Published online: 17 Jul 2023

References

  • Ai K, Zhu X, Kang Y, Li H, Zhang L. 2020. Mir-130a-3p inhibition protects against renal fibrosis in vitro via the tgf-beta1/smad pathway by targeting snon. Exper Mol Pathol. 112:104358. doi:10.1016/j.yexmp.2019.104358.
  • Allen AE, Martin EA, Greenwood K, Grant C, Vince P, Lucas RJ, Redfern WS. 2020. Effects of a monocarboxylate transport 1 inhibitor, azd3965, on retinal and visual function in the rat. Brit J Pharmacol. 177(20):4734–4749. doi:10.1111/bph.15239.
  • Bai M, Lei J, Wang S, Ding D, Yu X, Guo Y, Chen S, Du Y, Li D, Zhang Y, et al. 2019. Bmp1 inhibitor UK 383,367 attenuates renal fibrosis and inflammation in CKD. Amer J Physiol Renal Physiol. 317(6):F1430–F1438. doi:10.1152/ajprenal.00230.2019.
  • Baradaran Ghavami S, Chaleshi V, Derakhshani S, Aimzadeh P, Asadzadeh-Aghdaie H, Zali MR. 2017. Association between tnf-alpha rs1799964 and raf1 rs1051208 microrna binding site snp and gastric cancer susceptibility in an Iranian population. Gastroenterol Hepatol Bed Bench. 10(3):214–219.
  • Baumann F, Leukel P, Doerfelt A, Beier CP, Dettmer K, Oefner PJ, Kastenberger M, Kreutz M, Nickl-Jockschat T, Bogdahn U, et al. 2009. Lactate promotes glioma migration by tgf-beta2-dependent regulation of matrix metalloproteinase-2. Neurooncology. 11(4):368–380. doi:10.1215/15228517-2008-106.
  • Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. 2020. The dual role of tumor necrosis factor-alpha (tnf-alpha) in breast cancer: Molecular insights and therapeutic approaches. Cell Oncol (Dordr). 43(1):1–18. doi:10.1007/s13402-019-00489-1.
  • Del Prete E, Lutz TA, Scharrer E. 2004. Inhibition of glucose oxidation by alpha-cyano-4-hydroxycinnamic acid stimulates feeding in rats. Physiol Behav. 80(4):489–498. doi:10.1016/j.physbeh.2003.10.007.
  • Ding H, Jiang L, Xu J, Bai F, Zhou Y, Yuan Q, Luo J, Zen K, Yang J. 2017. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis. Amer J Physiol Renal Physiol. 313(3):F561–F575. doi:10.1152/ajprenal.00036.2017.
  • Drozdzik M, Szelag-Pieniek S, Grzegolkowska J, Lapczuk-Romanska J, Post M, Domagala P, Mietkiewski J, Oswald S, Kurzawski M. 2020. Monocarboxylate transporter 1 (mct1) in liver pathology. Intern J Mol Sci. 21(5) doi:10.3390/ijms21051606
  • Dufour AM, Alvarez M, Russo B, Chizzolini C. 2018. Interleukin-6 and type-i collagen production by systemic sclerosis fibroblasts are differentially regulated by interleukin-17a in the presence of transforming growth factor-beta 1. Front Immunol. 9:1865. doi:10.3389/fimmu.2018.01865.
  • Egli-Spichtig D, Imenez Silva PH, Glaudemans B, Gehring N, Bettoni C, Zhang MYH, Pastor-Arroyo EM, Schonenberger D, Rajski M, Hoogewijs D, et al. 2019. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney Intern. 96(4):890–905. doi:10.1016/j.kint.2019.04.009.
  • Guo C, Huang T, Wang QH, Li H, Khanal A, Kang EH, Zhang W, Niu HT, Dong Z, Cao YW. 2019. Monocarboxylate transporter 1 and monocarboxylate transporter 4 in cancer-endothelial co-culturing microenvironments promote proliferation, migration, and invasion of renal cancer cells. Cancer Cell Intern. 19:170. doi:10.1186/s12935-019-0889-8.
  • Hewitson TD, Smith ER. 2021. A metabolic reprogramming of glycolysis and glutamine metabolism is a requisite for renal fibrogenesis-why and how? Front Physiol. 12:645857. doi:10.3389/fphys.2021.645857.
  • Kaspar CD, Bholah R, Bunchman TE. 2016. A review of pediatric chronic kidney disease. Blood Purif. 41(1-3):211–217. doi:10.1159/000441737.
  • Lee M, Harley G, Katerelos M, Gleich K, Sullivan MA, Laskowski A, Coughlan M, Fraser SA, Mount PF, Power DA. 2020. Mutation of regulatory phosphorylation sites in pfkfb2 worsens renal fibrosis. Sci Rep. 10(1):14531. doi:10.1038/s41598-020-71475-z.
  • Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, Critchlow SE, Roux D, Simon MP, Pouyssegur J. 2011. Cd147 subunit of lactate/h+ symporters mct1 and hypoxia-inducible mct4 is critical for energetics and growth of glycolytic tumors. Proc Nat Acad Sci U.S.A. 108(40):16663–16668. doi:10.1073/pnas.1106123108.
  • Lemos DR, McMurdo M, Karaca G, Wilflingseder J, Leaf IA, Gupta N, Miyoshi T, Susa K, Johnson BG, Soliman K, et al. 2018. Interleukin-1beta activates a myc-dependent metabolic switch in kidney stromal cells necessary for progressive tubulointerstitial fibrosis. J Amer Soc Nephrol. 29(6):1690–1705. doi:10.1681/ASN.2017121283.
  • Lovisa S, Fletcher-Sananikone E, Sugimoto H, Hensel J, Lahiri S, Hertig A, Taduri G, Lawson E, Dewar R, Revuelta I, et al. 2020. Endothelial-to-mesenchymal transition compromises vascular integrity to induce myc-mediated metabolic reprogramming in kidney fibrosis. Sci Signal. 13(635) doi:10.1126/scisignal.aaz2597
  • Manning Fox JE, Meredith D, Halestrap AP. 2000. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol. 529(Pt 2):285–293. doi:10.1111/j.1469-7793.2000.00285.x.
  • Miranda-Goncalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, Cordeiro M, Bebiano G, Costa P, Palmeirim I, et al. 2013. Monocarboxylate transporters (mcts) in gliomas: Expression and exploitation as therapeutic targets. Neuro Oncol. 15(2):172–188. doi:10.1093/neuonc/nos298.
  • Perretta-Tejedor N, Munoz-Felix JM, Duwel A, Quiros-Luis Y, Fernandez-Martin JL, Morales AI, Lopez-Hernandez FJ, Lopez-Novoa JM, Martinez-Salgado C. 2019. Cardiotrophin-1 opposes renal fibrosis in mice: Potential prevention of chronic kidney disease. Acta Physiol. 226(2):e13247. doi:10.1111/apha.13247.
  • Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, et al. 2013. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 19(4):488–493. doi:10.1038/nm.3092.
  • Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, Saedeleer D, Kennedy CJ, Diepart KM, Jordan C, F B, et al. 2008. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 118(12):3930–3942. doi:10.1172/JCI36843.
  • Tan C, Gu J, Li T, Chen H, Liu K, Liu M, Zhang H, Xiao X. 2021. Inhibition of aerobic glycolysis alleviates sepsisinduced acute kidney injury by promoting lactate/sirtuin 3/ampkregulated autophagy. Intern J Mol Med. 47(3) doi:10.3892/ijmm.2021.4852
  • Uddin M, Kawami M, Yumoto R, Takano M. 2020. Effect of transforming growth factor-beta1 on functional expression of monocarboxylate transporter 1 in alveolar epithelial a549 cells. Naunyn-Schmiedeberg's Arch Pharmacol. 393(5):889–896. doi:10.1007/s00210-019-01802-3.
  • Wang L, Zhu R, Wang J, Yu S, Wang J, Zhang Y. 2020. Nrf2 activation enhances muscular mct1 expression and hypoxic exercise capacity. Med Sci Sports Exerc. 52(8):1719–1728. doi:10.1249/MSS.0000000000002312.
  • Waters JP, Pober JS, Bradley JR. 2013. Tumour necrosis factor and cancer. J Pathol. 230(3):241–248. doi:10.1002/path.4188.
  • Yuan B, Peng Q, Cheng J, Wang M, Zhong J, Qi J, Gao GF, Shi Y. 2022. Structure of the ebola virus polymerase complex. Nature. 610(7931):394–401. doi:10.1038/s41586-022-05271-2.
  • Zhang G, Darshi M, Sharma K. 2018a. The warburg effect in diabetic kidney disease. Sem Nephrol. 38(2):111–120. doi:10.1016/j.semnephrol.2018.01.002.
  • Zhang G, Zhang Y, Dong D, Wang F, Ma X, Guan F, Sun L. 2018b. Mct1 regulates aggressive and metabolic phenotypes in bladder cancer. J Cancer. 9(14):2492–2501. doi:10.7150/jca.25257.
  • Zhang Y, Dai Y, Raman A, Daniel E, Metcalf J, Reif G, Pierucci-Alves F, Wallace DP. 2020. Overexpression of tgf-beta1 induces renal fibrosis and accelerates the decline in kidney function in polycystic kidney disease. Amer J Physiol Renal Physiol. 319(6):F1135–F1148. doi:10.1152/ajprenal.00366.2020.
  • Zhou HL, Zhang R, Anand P, Stomberski CT, Qian Z, Hausladen A, Wang L, Rhee EP, Parikh SM, Karumanchi SA, et al. 2019. Metabolic reprogramming by the s-nitroso-coa reductase system protects against kidney injury. Nature. 565(7737):96–100. doi:10.1038/s41586-018-0749-z.